Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma

Background: Given the significant activity and tolerability of gemcitabine in patients with relapsed Hodgkin's lymphoma (HL), the critical role that nuclear factor kappa B (NF-κB) appears to play in the pathogenesis of this tumor, the ability of bortezomib to inhibit NF-κB activity, and laborat...

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Main Authors:	Mendler, J. H., Kelly, J., Voci, S., Marquis, D., Rich, L., Rossi, R. M., Bernstein, S. H., Jordan, C. T., Liesveld, J., Fisher, R. I., Friedberg, J. W.
Format:	Artigo
Sprog:	Inglês
Udgivet:	Oxford University Press 2008
Fag:	Original Articles
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC2735068/ https://ncbi.nlm.nih.gov/pubmed/18504251 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdn365
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma

Lignende værker